CytomX Therapeutics, Inc.
CTMXUS売上高
$76M
百万USD
営業利益
$-22M
百万USD
純利益
$-17M
百万USD
ROE
-17.5%
最新FY
EPS
-
USD / 株
配当
-
USD / 株
業績推移
収益性
キャッシュフロー
財務状況
四半期業績
| 年度 | 期 | 売上高 | 純利益 | EPS |
|---|---|---|---|---|
| FY2021 | Q1 | $16M | $-16M | - |
| FY2021 | Q2 | $16M | $-19M | - |
| FY2021 | Q3 | $18M | $-23M | - |
| FY2021 | FY | $37M | $-116M | - |
| FY2022 | Q1 | $17M | $-24M | - |
| FY2022 | Q2 | $18M | $-24M | - |
| FY2022 | Q3 | $17M | $-23M | - |
| FY2022 | FY | $53M | $-99M | - |
| FY2023 | Q1 | $23M | $-3M | - |
| FY2023 | Q2 | $25M | $-1M | - |
| FY2023 | Q3 | $26M | $3M | - |
| FY2023 | FY | $101M | $-1M | - |
| FY2024 | Q1 | $41M | $14M | - |
| FY2024 | Q2 | $25M | $-7M | - |
| FY2024 | Q3 | $33M | $6M | - |
| FY2024 | FY | $138M | $32M | - |
| FY2025 | Q1 | $51M | $24M | - |
| FY2025 | Q2 | $19M | $-0M | - |
| FY2025 | Q3 | $6M | $-14M | - |
| FY2025 | FY | $76M | $-17M | - |
| FY2026 | Q1 | $10M | $-18M | - |
財務データ
| 指標 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 売上高 | - | - | $60M | $57M | $100M | $37M | $53M | $101M | $138M | $76M |
| 営業利益 | $-60M | $-46M | $-78M | $-111M | $-49M | $-116M | $-101M | $-6M | $25M | $-22M |
| 純利益 | $-59M | $-43M | $-85M | $-102M | $-33M | $-116M | $-99M | $-1M | $32M | $-17M |
| 総資産 | $199M | $398M | $457M | $341M | $359M | $339M | $261M | $202M | $121M | $152M |
| 純資産 | - | - | - | - | - | - | - | - | - | - |
| 自己資本 | $78M | $70M | $131M | $51M | $50M | $-0M | $-86M | $-47M | $-0M | $99M |
| 営業CF | - | - | $-76M | $-140M | $5M | $-119M | $-111M | $-56M | $-86M | $-76M |
| EPS | - | - | - | - | - | - | - | - | - | - |
| BPS | $2.15 | $1.81 | $2.90 | $1.12 | $0.77 | $-0.01 | $-1.29 | $-0.70 | $-0.01 | $0.58 |
| ROE | -75.1% | -61.7% | -64.6% | -200.0% | -66.0% | 25244.0% | 115.8% | 1.2% | -6988.8% | -17.5% |